biostudies-literatureUnknown25(1)Niemann MCharité - Universitätsmedizin Berlin<h4>Objective</h4>Platelet-rich plasma (PRP) therapy is increasingly popular to treat musculoskeletal diseases, including tendinopathies and osteoarthritis (OA). To date, it remains unclear to which extent PRP compositions are determined by the immune cell and cytokine profile of individuals or by the preparation method. To investigate this, we compared leukocyte and cytokine distributions of different PRP products to donor blood samples and assessed the effect of pro-inflammatory cytokines on chondrocytes.<h4>Design</h4>For each of three PRP preparations (ACP®, Angel™, and nSTRIDE® APS), products were derived using whole blood samples from twelve healthy donors. The cellular composition of PRP products was analyzed by flow cytometry using DURAClone antibody panels (DURAClone IM PhenotypinArthritis research & therapy6https://www.ebi.ac.uk/biostudies/studies/S-EPMC9830842biostudies-literatureIndividual immune cell and cytokine profiles determine platelet-rich plasma composition.PMC9830842Wilhelm ALauterbach LDuda GNReinke SMaleitzke TOrt MPerka CGeißler SGraef FFleckenstein FNBlankenstein AStockle UWinkler TGrutz GNiemann MStreitz MfalseIndividual immune cell and cytokine profiles determine platelet-rich plasma composition.<h4>Objective</h4>Platelet-rich plasma (PRP) therapy is increasingly popular to treat musculoskeletal diseases, including tendinopathies and osteoarthritis (OA). To date, it remains unclear to which extent PRP compositions are determined by the immune cell and cytokine profile of individuals or by the preparation method. To investigate this, we compared leukocyte and cytokine distributions of different PRP products to donor blood samples and assessed the effect of pro-inflammatory cytokines on chondrocytes.<h4>Design</h4>For each of three PRP preparations (ACP®, Angel™, and nSTRIDE® APS), products were derived using whole blood samples from twelve healthy donors. The cellular composition of PRP products was analyzed by flow cytometry using DURAClone antibody panels (DURAClone IM Phenotypin2023-01-01T00:00:00Z2023 Jan2026-03-15T12:49:12.125Z2025-04-04T09:18:58.533ZS-EPMC98308423662772110.1186/s13075-022-02969-6